TRAIL compounds and agonists targeting DR5 (Dubuisson and Micheau, 2017) for treatment of numerous cancer types are highly developed in the clinic, providing further rationale to investigate this cytokine further as a widely applicable p53 target that may induce apoptosis and an immune response across numerous cancer types (Falschlehner et al., 2009; Ralff and El-Deiry, 2018). Here, TNFSF10 is linked to cancer.